The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The investigators are conducting a pilot trial where they will study safety, efficacy and
compliance in a cohort of ambulatory patients in the Ghent region with confirmed COVID-19
infection, in both an early stage of disease, defined as less than 5 days of symptoms and who
at presentation do not meet any criteria for hospitalisation as well as asymptomatic
individuals with a PCR CT value below 30.
The primary endpoint is to assess the efficacy of the drug in terms of change from day 0 to
day 5 in respiratory (oropharyngeal swab RT-PCR) log10 viral load.
The aim of the study is to assess whether Camostat, a serine protease inhibitor available in
an oral formulation has the potential to be studied as an antiviral drug in a large scale
ambulatory setting to prevent transmission by decreasing viral load, to prevent symptoms
after exposure (PEP) in asymptomatic individuals or to prevent disease progression in the
occurrence of early symptomatology.